Nuclera Unicorn Score: 71/100
Cambridge, United KingdomNuclera is a biotechnology company developing an automated multiplex protein screening system, the eProtein Discovery platform. This system enables researchers to rapidly obtain active proteins from DNA within 48 hours, significantly accelerating drug discovery workflows and removing uncertainty from protein science.
Valuation track record
- First screened
- May 25, 2026
- Entry valuation
- $100M
- Current valuation
- $100M
Latest valuation verified from Live re-screening on May 25, 2026. Updated quarterly from public funding announcements.
Founders
Michael Chen
CEO and Co-Founder
Gordon McInroy
COO and Co-Founder
Jiahao Huang
CFO and Co-Founder
Get the full Nuclera report
Founders deep-dive, traction signals, market thesis, red flags, scoring breakdown and an audio summary, delivered to your inbox.
Frequently asked
What is Nuclera's unicorn score?
Nuclera has a Unicorn Screener score of 71/100, classified as "Promising". Recommended action: watchlist.
What is Nuclera's current valuation?
Nuclera's most recently verified valuation is $100M, last checked on May 25, 2026 (source: Live re-screening).
What sector is Nuclera in?
Nuclera operates in the Biotech sector and is headquartered in Cambridge, United Kingdom.
When was Nuclera first screened?
Nuclera was first screened by Unicorn Screener on May 25, 2026, with an entry valuation of $100M.